The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Neuropathologic Correlates of Psychiatric Symptoms in Alzheimer’s Disease
Open accessAbstract
Clarifying the relationships between neuropsychiatric symptoms and Alzheimer’s disease (AD)-related pathology may open avenues for effective treatments. Here, we investigate the odds of developing neuropsychiatric symptoms across increasing burdens of neurofibrillary tangle and amyloid-β pathology. Participants who passed away between 2004 and 2014 underwent comprehensive neuropathologic evaluation at the Biobank for Aging Studies from the Faculty of Medicine at the University of São Paulo. Postmortem interviews with reliable informants were used to collect information regarding neuropsychiatric and cognitive status. Of 1,092 cases collected, those with any non-Alzheimer pathology were excluded, bringing the cohort to 455 cases. Braak staging was used to evaluate neurofibrillary tangle burden, and the CERAD neuropathology score was used to evaluate amyloid-β burden. The 12-item neuropsychiatric inventory was used to evaluate neuropsychiatric symptoms and CDR-SOB score was used to evaluate dementia status. In Braak I/II, significantly increased odds were detected for agitation, anxiety, appetite changes, depression, and sleep disturbances, compared to controls. Increased odds of agitation continue into Braak III/IV. Braak V/VI is associated with higher odds for delusions. No increased odds for neuropsychiatric symptoms were found to correlate with amyloid-β pathology. Increased odds of neuropsychiatric symptoms are associated with early neurofibrillary tangle pathology, suggesting that subcortical neurofibrillary tangle accumulation with minimal cortical pathology is sufficient to impact quality of life and that neuropsychiatric symptoms are a manifestation of AD biological processes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568 · cited 11×
“Braak stage I-II did not correlate with higher odds for any of the other seven NPI domains, aligning with the primary analysis.”
InfluentialSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894 · cited 1×
“AD is characterized by the accumulation of neurofibrillary tangles (NFT) and amyloid-(cid:2) plaques, as well as neuron loss [2].”
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194
Belmaker, R. H., & Agam, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra073096 · Cited by 2,166
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Ownby, R. L., Crocco, E., Acevedo, A., John, V., & Loewenstein, D. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.5.530 · Cited by 1,493
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489
PET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214
Neuropsychiatric symptoms in Alzheimer's disease
Lyketsos, C. G., Carrillo, M. C., Ryan, J. M., Khachaturian, A. S., Trzepacz, P., Amatniek, J., Cedarbaum, J., Brashear, R., & Miller, D. S. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2410 · Cited by 1,139
Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease
Giannakopoulos, P., Herrmann, F. R., Bussière, T., Bouras, C., Kövari, E., Perl, D. P., Morrison, J. H., Gold, G., & Hof, P. R. (2003) · Neurology · doi:10.1212/01.wnl.0000063311.58879.01 · Cited by 1,118 · cited 1×
“Neuron loss is the best predictor of cognitive decline, followed by NFT burden [3, 4].”
Ruhé, H. G., Mason, N. S., & Schene, A. H. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001949 · Cited by 861
The pathological process underlying Alzheimer’s disease in individuals under thirty
Braak, H., & Del Tredici, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-010-0789-4 · Cited by 812
Human Fear Conditioning and Extinction in Neuroimaging: A Systematic Review
Sehlmeyer, C., Schöning, S., Zwitserlood, P., Pfleiderer, B., Kircher, T., Arolt, V., & Konrad, C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005865 · Cited by 543
Theofilas, P., Ehrenberg, A. J., Dunlop, S., Di Lorenzo Alho, A. T., Nguy, A., Leite, R. E. P., Rodriguez, R. D., Mejia, M. B., Suemoto, C. K., Ferretti-Rebustini, R. E. D. L., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.2362 · Cited by 416
Self-citationNeuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms
Lanctôt, K. L., Amatniek, J., Ancoli‐Israel, S., Arnold, S. E., Ballard, C., Cohen‐Mansfield, J., Ismail, Z., Lyketsos, C., Miller, D. S., Musiek, E., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.07.001 · Cited by 395
The importance of norepinephrine in depression
Briley, M., & Chantal, M. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s19619 · Cited by 373 · cited 1×
“Instead, early NFT-induced dysfunc-tionofneuronsinthelocuscoeruleusanddorsalraphe nucleus is likely driving our findings of increased odds for depression in Braak stages I/II, in line with the monoamine hypothesis of depression [53, 68–70].”
Identification of preoptic sleep neurons using retrograde labelling and gene profiling
Chung, S., Weber, F., Zhong, P., Tan, C. L., Nguyen, T. N., Beier, K. T., Hörmann, N., Chang, W.-C., Zhang, Z., Do, J. P., et al. (2017) · Nature · doi:10.1038/nature22350 · Cited by 317
Depressive Symptoms and Cognitive Decline in Late Life: A Prospective Epidemiological Study
Ganguli, M., Du, Y., Dodge, H. H., Ratcliff, G. G., & Chang, C.-C. H. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.153 · Cited by 314
Chronic Psychological Distress and Risk of Alzheimer’s Disease in Old Age
Wilson, R. S., Arnold, S. E., Schneider, J. A., Kelly, J. F., Tang, Y., & Bennett, D. A. (2006) · Neuroepidemiology · doi:10.1159/000095761 · Cited by 266
Structural correlates of apathy in Alzheimer's disease
Apostolova, L. G., Akopyan, G. G., Partiali, N., Steiner, C. A., Dutton, R. A., Hayashi, K. M., Dinov, I. D., Toga, A. W., Cummings, J. L., & Thompson, P. M. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000103914 · Cited by 190
Brazilian Aging Brain Study Group, Grinberg, L. T., de Lucena Ferretti, R. E., Farfel, J. M., Leite, R., Pasqualucci, C. A., Rosemberg, S., Nitrini, R., Saldiva, P. H. N., & Jacob Filho, W. (2007) · Cell and Tissue Banking · doi:10.1007/s10561-006-9022-z · Cited by 169
Self-citationNeuroimaging in anxiety disorders
Holzschneider, K., & Mulert, C. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/kholzschneider · Cited by 146
Age-related cognitive decline in patients with mood disorders
Gualtieri, C. T., & Johnson, L. G. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.12.030 · Cited by 80
Tau phosphorylation in human brain: relationship to behavioral disturbance in dementia
Guadagna, S., Esiri, M. M., Williams, R. J., & Francis, P. T. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.01.015 · Cited by 48
Eurelings, L. S. M., Richard, E., Eikelenboom, P., van Gool, W. A., & Moll van Charante, E. P. (2015) · International Psychogeriatrics · doi:10.1017/s1041610214002683 · Cited by 38
Cited by
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
RetractedLocus coeruleus: a new look at the blue spot
Poe, G. R., Foote, S., Eschenko, O., Johansen, J. P., Bouret, S., Aston-Jones, G., Harley, C. W., Manahan-Vaughan, D., Weinshenker, D., Valentino, R., et al. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0360-9 · Cited by 720
Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases
Betts, M. J., Kirilina, E., Otaduy, M. C. G., Ivanov, D., Acosta-Cabronero, J., Callaghan, M. F., Lambert, C., Cardenas-Blanco, A., Pine, K., Passamonti, L., et al. (2019) · Brain · doi:10.1093/brain/awz193 · Cited by 365
Self-citationPsychosis in Alzheimer disease—mechanisms, genetics and therapeutic opportunities
Ismail, Z., Creese, B., Aarsland, D., Kales, H. C., Lyketsos, C. G., Sweet, R. A., & Ballard, C. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00597-3 · Cited by 189
Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance
Nehra, G., Bauer, B., & Hartz, A. M. S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108119 · Cited by 127
Metadata
- Authors
- Ehrenberg, A. J., Suemoto, C. K., França Resende, E. D. P., Petersen, C., Leite, R. E. P., Rodriguez, R. D., Ferretti-Rebustini, R. E. D. L., You, M., Oh, J., Nitrini, R., Pasqualucci, C. A., Jacob-Filho, W., Kramer, J. H., Gatchel, J. R., & Grinberg, L. T.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2018-09-07
- Volume
- 66
- Issue
- 1
- Pages
- 115-126
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2890722904
- Cited by
- 214
- References
- 34
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.